Michael Huss Selected Research

Guanfacine (Tenex)

1/2020	Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder.
1/2019	Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
10/2018	Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD.
8/2017	Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.
1/2016	Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment.
1/2016	Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
1/2016	Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.
12/2014	Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Huss Research Topics

Disease

30	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 03/2022 - 01/2004
2	Feeding and Eating Disorders (Eating Disorder) 01/2019 - 01/2016
2	Sleepiness 01/2019 - 10/2018
2	Disorders of Excessive Somnolence (Hypersomnia) 01/2019 - 10/2018
2	Anxiety Disorders (Anxiety Disorder) 01/2018 - 08/2017
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 08/2021
1	Psychotic Disorders (Schizoaffective Disorder) 07/2021
1	Disease Progression 07/2021
1	Psychomotor Agitation (Akathisia) 11/2020
1	Hyperhidrosis 11/2020
1	Infections 11/2020
1	Human Influenza (Influenza) 11/2020
1	Syncope (Fainting) 11/2020
1	Tachycardia (Tachyarrhythmias) 11/2020
1	Tonsillitis 11/2020
1	Oppositional Defiant Disorder 01/2020
1	Alcoholism (Alcohol Abuse) 07/2012
1	Mood Disorders (Mood Disorder) 10/2010
1	Schizophrenia (Dementia Praecox) 10/2010
1	Apraxias (Dyspraxia) 02/2010
1	Neurocognitive Disorders (Clerambault Syndrome) 02/2010
1	Autism Spectrum Disorder 02/2010
1	Dyslexia (Alexia) 02/2010
1	Conduct Disorder (Conduct Disorders) 01/2004

Drug/Important Bio-Agent (IBA)

15	Methylphenidate (Ritalin)FDA LinkGeneric 01/2022 - 01/2005
8	Guanfacine (Tenex)FDA LinkGeneric 01/2020 - 12/2014
6	Pharmaceutical PreparationsIBA 07/2021 - 04/2010
4	Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric 08/2017 - 01/2012
2	N-(2-acetamido)-2-aminoethanesulfonic acid (ACES)IBA 03/2022 - 08/2021
2	5'-palmitoyl cytarabine (PLAC)IBA 11/2020 - 03/2014
2	Hypnotics and Sedatives (Sedatives)IBA 01/2019 - 10/2018
2	N- succinimidyl- 4- ((iodoacetyl)amino)benzoateIBA 01/2019 - 01/2016
2	VortioxetineIBA 01/2018 - 08/2017
1	Sulfates (Sulfates, Inorganic)IBA 01/2021
1	Dextroamphetamine (Dexedrine)FDA LinkGeneric 01/2021
1	Lisdexamfetamine Dimesylate FDA Link 08/2017
1	Central Nervous System StimulantsIBA 01/2017
1	Dopamine (Intropin)FDA LinkGeneric 01/2016
1	Catecholamine ReceptorsIBA 01/2016
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2016
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2016
1	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 01/2016
1	Omega-6 Fatty Acids (Omega 6 Fatty Acids)IBA 02/2010
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 02/2010
1	4,4'-dibenzamido-2,2'-stilbenedisulfonic acidIBA 01/2004

Therapy/Procedure

6	Therapeutics 01/2022 - 01/2004
4	Drug Therapy (Chemotherapy) 07/2019 - 01/2004
3	Combined Modality Therapy 01/2022 - 03/2014